Novartis is joining the migration of the major players directly into the heart of the world’s biggest biotech R&D hubs.
The Basel-based pharma giant put out word today that they have decided to relocate their headquarters in the UK from their site at Frimley in Surrey to a new campus bordering Imperial College London’s research and innovation campus. That will trigger the relocation of some 600 staffers to 54,000-square-feet at The WestWorks, part of the rebirth of the old BBC Media Village campus in the White City area that is now home to a group of British biotech players.
The move-in is planned for the beginning of 2020.
Novartis UK chief Haseeb Ahmad was careful to frame the move as fitting into new CEO Vas Narasimhan’s slogan to “reimagine medicine.”
White City is quickly becoming one of the UK’s life sciences and technology districts, and the ethos of The WestWorks campus complements how we work to deliver on our strategy to reimagine medicine.
The news will be welcome on Downing Street. The UK government has been trying to reassure the biopharma industry that their future will remain bright after Brexit — even as the simmering controversy over their departure from the EU turns into a full fledged political crisis. And any signs of growth or commitment to the UK in the industry is greeted with considerable enthusiasm.
Image: WestWorks. WHITE CITY PLACE
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.Free Subscription